There are currently 168 active clinical trials seeking participants for Heart Failure research studies. The states with the highest number of trials for Heart Failure participants are California, Florida, Texas and New York.
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
NCT05636176
Recruiting
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to u... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +989 locations
Conditions: Heart Failure
Register for Updates
Assessment of Combined CCM and ICD Device in HFrEF
NCT05855135
Recruiting
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced le... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Phoenix Heart, Glendale, Arizona +55 locations
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation
Register for Updates
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
NCT06062966
Recruiting
End-stage heart failure (HF) is a progressive illness with a mortality rate similar to most advanced cancers.Roughly 5% of patients with HF have end-stage disease that is refractory to medical therapy (stage D heart failure). When patients reach this point in their disease, the only treatments known to prolong life are cardiac transplantation or left ventricular assist devices. In patients who do not qualify for these options, or elect a palliative approach, inotropes are frequently used to impr... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/25/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Heart Failure
Register for Updates
Pilot Study Lp299v Supplementation in Chronic Heart Failure
NCT05752760
Recruiting
The goal of this study is to determine the impact of 12 weeks of Lp299v supplementation (20 million cfu/day vs. placebo) on exercise capacity, circulating biomarkers of cardiac remodeling, quality of life, and vascular endothelial function in humans with heart failure and reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) who have evidence of residual inflammation based on an elevated C-reactive protein level. This will be done in the setting of a random... Read More
Gender:
ALL
Ages:
Between 21 years and 89 years
Trial Updated:
04/24/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure, Systolic, Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic
Register for Updates
Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation
NCT06130059
Recruiting
The purpose of this research study is to determine the effectiveness of low dose colchicine (LoDoCo) on measures of exercise capacity, physical function, frailty, and quality of life, among patients with heart failure with chronic stable preserved ejection fraction (HFpEF) and systemic inflammation. The use of LoDoCo in this study is considered investigational as it has not been approved by the Food and Drug Administration (FDA) for the treatment of exercise capacity in patients with HFpEF. Par... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/23/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Heart Failure, Inflammation
Register for Updates
The Re-Prosper HF Study
NCT04551222
Recruiting
Heart failure with reduced ejection fraction (HFrEF) is a common cause for admission within the Veterans Affairs (VA) Health Care System. It is associated with severe impairment of physical and mental health status and carries a high risk of mortality. Even though significant progress has been made in understanding the disease process, currently, its management and treatment is limited. The investigators have discovered that a commonly used drug for the treatment of gout can be repurposed for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts +4 locations
Conditions: Heart Failure
Register for Updates
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970
Recruiting
This will be a global Phase IV, open-label, randomised study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally \[po\], twice daily \[bd\]) compared to investigator's choice of treatment, in patients with CLL (TN or R/R) and moderate to severe cardiac impairment. All patients will have cardiac impairment as defined by LVEF of \< 50%. Randomisation will be stratified by LVEF \> 40% vs ≤ 40% to stratify for moderate and severe cardiac impairment, which for this s... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/23/2025
Locations: Research Site, Charlotte, North Carolina +22 locations
Conditions: Chronic Lymphocytic Leukaemia, Heart Failure
Register for Updates
Decision Support for Heart Failure Prescribing
NCT06293794
Recruiting
Clinical decision support (CDS) tools can 'nudge' clinicians to make the best decisions easy. Although required by "meaningful use" regulations, more than 40% of CDS lead to no change and the remaining lead to improvements that are modest at best. This is because CDS tools often ignore contextual factors and present irrelevant information. Although many tools have undergone patient-specific optimization, 'traditional CDS' are rarely clinician-specific. For example, a traditional CDS tool for bet... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/22/2025
Locations: UCHealth Primary Care and Cardiology Outpatient Clinics, Aurora, Colorado
Conditions: Decision Support Systems, Clinical, Heart Failure
Register for Updates
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
NCT05686317
Recruiting
This is a prospective, multi-center, randomized, sham-controlled, double-blinded (participant and outcomes assessor) clinical trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: University of California Irvine, Irvine, California +29 locations
Conditions: Heart Failure
Register for Updates
Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure
NCT06253104
Recruiting
This study aims to determine, via skeletal muscle ultrasound (US), the extent, timing and relationship between skeletal muscle mass loss and outcomes after orthotropic heart transplantation (OHT) and left ventricular assist device (LVAD) implantation amongst patients with cardiogenic shock. Advanced therapies such as OHT and VADs in the heart failure (HF) population may promote skeletal muscle mass and subsequent quality of life, but there is a lack of literature assessing muscle mass changes in... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/18/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Heart Failure, Muscle Atrophy, Skeletal Muscle Atrophy, Cardiogenic Shock
Register for Updates
TEXT4HF: A Randomized Controlled Trial of a Tailored Text Messaging Intervention to Improve Self-Care in Older Adult Patients With Heart Failure
NCT06473532
Recruiting
The goal of this study is to determine whether an individually tailored text messaging intervention can improve self-care in older adult patients with heart failure. The main question it aims to answer are: * Is a tailored text messaging intervention feasible and acceptable among older adult patients with heart failure? * Does tailored text messaging improve self-care in adult patients with heart failure? Participants will be randomly assigned to one of two groups for 12 weeks: 1) intervention... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/16/2025
Locations: University of Illinois, Chicago, Chicago, Illinois
Conditions: Heart Failure
Register for Updates
Splanchnic X: Splanchnic Nerve Block in Heart Failure With Reduced Ejection Fraction
NCT06733012
Recruiting
Heart failure (HF) affects more than 6 million adults in the U.S. alone, with increasing prevalence. Cardiovascular congestion with resultant limitation in physical activity is the hallmark of chronic and decompensated HF. The current HF physiologic model suggests that congestion is the result of volume retention and, therefore, therapies (such as diuretics) have generally been targeted at volume overload. Yet therapeutic approaches to reduce congestion have failed to show significant benefit on... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Duke, Durham, North Carolina
Conditions: Heart Failure
Register for Updates